Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer

[1]  E. King,et al.  Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs , 2022, Nature.

[2]  Vijay Kumar Chattu,et al.  Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 , 2021, JAMA oncology.

[3]  A. Italiano,et al.  Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review , 2021, Frontiers in Immunology.

[4]  A. Schneeweiss,et al.  First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  X. Guan,et al.  Progress and challenges of immunotherapy in triple-negative breast cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[6]  Potential for Long-Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA-Mutated Advanced Breast Cancer. , 2021, The oncologist.

[7]  K. Okkenhaug,et al.  PI3K inhibitors are finally coming of age , 2021, Nature Reviews Drug Discovery.

[8]  B. Hall,et al.  Multiple sclerosis patients have reduced resting and increased activated CD4+CD25+FOXP3+T regulatory cells , 2021, Scientific Reports.

[9]  L. Zitvogel,et al.  Immunomodulation by targeted anticancer agents. , 2020, Cancer cell.

[10]  M. Campone,et al.  Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer , 2020, Therapeutic advances in medical oncology.

[11]  K. Pilipow,et al.  T-cell-Based Breast Cancer Immunotherapy. , 2020, Seminars in cancer biology.

[12]  Bing-he Xu,et al.  Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. , 2020, Current problems in cancer.

[13]  F. Bertucci,et al.  Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[15]  D. Demarini,et al.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. , 2019, Blood.

[16]  K. Okkenhaug,et al.  Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. , 2018, JCI insight.

[17]  T. Schumacher,et al.  Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.

[18]  S. Loi,et al.  Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer , 2018, Clinical Cancer Research.

[19]  L. Emens.  Breast Cancer Immunotherapy: Facts and Hopes , 2017, Clinical Cancer Research.

[20]  Lewis C. Cantley,et al.  The PI3K Pathway in Human Disease , 2017, Cell.

[21]  F. Marincola,et al.  Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. , 2017, European journal of cancer.

[22]  J. Janik,et al.  Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition. , 2017, Cancer research.

[23]  Norikazu Masuda,et al.  Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[24]  S. Khleif,et al.  Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy. , 2017, Cancer research.

[25]  M. Campone,et al.  Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy , 2017, Therapeutic advances in medical oncology.

[26]  H. Kohrt,et al.  Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  M. Ellis,et al.  Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. , 2016, The Lancet. Oncology.

[28]  Carsten Denkert,et al.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.

[29]  P. Marchetti,et al.  Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. , 2016, Critical reviews in oncology/hematology.

[30]  F M Blows,et al.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Berzofsky,et al.  Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway , 2014, Cancer Immunology Research.

[32]  Dalya R. Soond,et al.  Inactivation of the PI3K p110δ breaks regulatory T cell-mediated immune tolerance to cancer , 2014, Nature.

[33]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[34]  E. Holler,et al.  Isolation of CD4+CD25+ regulatory T cells for clinical trials. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  K. Okkenhaug,et al.  PI3K in lymphocyte development, differentiation and activation , 2003, Nature Reviews Immunology.

[36]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.